The Rotavac vaccine, which is a culmination of efforts spanning 28 years, has an efficacy of 56 per cent if administered in the first year of life, according to scientists who released the results of the Phase III clinical trials of the vaccine.
"Rotavac significantly reduced severe rotavirus diarrhoea by more than half," M K Bhan, former Secretary, Department of Biotechnology, who isolated the rotavirus strain in 1985 while pursuing research at AIIMS, told reporters here.
"We are planning to file a dossier with the DCGI in July. We will come to the market after getting the requisite regulatory clearances," Krishna M Ella, Chairman and Managing Director, Bharat Biotech, said.
Bharat Biotech, which has been associated in the development of vaccine candidates and clinical trials, has announced a price of USD one (about Rs 54.7 )per dose--much cheaper than other rotavirus vaccines available in the market. The price of the vaccine now used is in the range of Rs 800 to 900.
"The results indicate that the vaccine, if licensed, could save the lives of thousands of children each year in India," K Vijay Raghavan, Secretary, Department of Biotechnology, said.
Rotavac is an oral vaccine administered to infants in a three-dose course at the ages of six, 10 and 14 weeks alongside routine immunisations recommended at these ages.
According to a study in Lancet, Rotavirus is most common causative agent of moderate-to-severe diarrhoea (MSD) among infants below 11 months age group in India.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
